Skinvisible (SKVI) Net Income towards Common Stockholders (2010 - 2026)
Skinvisible's (SKVI) quarterly Net Income towards Common Stockholders came in at -$255533.0 in Q2 2026, up 8.4% year-over-year from -$235738.1 in Q2 2025, and up 4.36% quarter-over-quarter from -$267184.0 in Q1 2026.
Powered by 
Analysis
Skinvisible (SKVI) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Skinvisible has disclosed Net Income towards Common Stockholders across 17 years of filings, most recently posting -$255533.0 for Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 8.4% year-over-year to -$255533.0; the TTM figure through Jun 2026 stood at -$1.0 million (up 15.47% YoY), while the FY2025 annual figure was -$1.1 million, up 15.13% from the prior year.
- Net Income towards Common Stockholders came in at -$255533.0 for Q2 2026 at Skinvisible, up from -$267184.0 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$204955.0 in Q2 2022 to a low of -$1.5 million in Q1 2023.
- Average Net Income towards Common Stockholders over 5 years is -$368838.8, with a median of -$288945.0 recorded in 2023.
- Year-over-year, Net Income towards Common Stockholders tumbled 310.46% in 2023 and jumped 80.83% in 2024.
- Over 5 years, Net Income towards Common Stockholders stood at -$408893.0 in 2022, then grew by 25.7% to -$303791.0 in 2023, then declined by 20.94% to -$367406.0 in 2024, then rose by 29.68% to -$258357.0 in 2025, then rose by 1.09% to -$255533.0 in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$255533.0 in Q2 2026, -$267184.0 in Q1 2026, and -$258357.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.02 Bn | 629.26 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 443.38 Bn | 436.81 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 368.22 Bn | 361.07 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 270.16 Bn | 262.47 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Pfizer | 158.63 Bn | 146.93 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Sanofi | 52.92 Bn | 45.54 Bn | 10.79 Bn | 398.69 Mn |
| 7 | Revolution Medicines | 44.49 Bn | 44.49 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.22 Bn | 20.69 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.17 Bn | 18.51 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Skinvisible | 1.08 Mn | 1.08 Mn | 5,000.00 | -255,533.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -255,533.00 |
| Mar 31, 2026 | -267,184.00 |
| Dec 31, 2025 | -258,357.00 |
| Sep 30, 2025 | -250,245.00 |
| Jun 30, 2025 | -278,957.00 |
| Mar 31, 2025 | -281,005.00 |
| Dec 31, 2024 | -367,406.00 |
| Sep 30, 2024 | -292,726.00 |
| Jun 30, 2024 | -309,303.00 |
| Mar 31, 2024 | -290,372.00 |
| Dec 31, 2023 | -303,791.00 |
| Sep 30, 2023 | -287,518.00 |
| Jun 30, 2023 | -280,345.00 |
| Mar 31, 2023 | -1.52 Mn |
| Dec 31, 2022 | -408,893.00 |
| Sep 30, 2022 | -418,345.00 |
| Jun 30, 2022 | -204,955.00 |
| Mar 31, 2022 | -369,108.00 |
| Dec 31, 2021 | -461,660.00 |
| Sep 30, 2021 | -203,352.00 |